Completed PHASE1 INTERVENTIONAL 1-arm NCT01236443

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

A Phase I/II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for the Treatment of High Grade Dysplasia, Carcinoma-in-situ and Early Adenocarcinoma in Barrett's Esophagus

Sponsor: Roswell Park Cancer Institute

Conditions Barrett's Esophagus CIS High Grade Dysplasia

Interventions HPPH

Updated 6 times since 2017 Last updated: Jan 10, 2014 Started: Aug 31, 2000 Primary completion: May 31, 2003 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01236443, this PHASE1 trial focuses on Barrett's Esophagus and CIS and remains completed. Sponsored by Roswell Park Cancer Institute, it has been updated 6 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roswell Park Cancer Institute

Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States